IL2 and neoplasm: Importantly, combination of imiquimod and IL-2 without peptide and CD3 bsAb did not result in better survival outcomes compared to CD3xTRP1 alone, indicating that addition of the vaccine peptide is required for the anti-tumor activity (Supplementary Fig. 9e, f).